Drug intelligence / Profile preview

UVAX-1107 + UVAX-1197

Development stage: Unknown
Lead developer: Uvax Bio
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

UVAX-1107 + UVAX-1197 is a combination of two investigational HIV-1 vaccine candidates developed by Uvax Bio. These vaccines are protein-based nanoparticle biologics utilizing the proprietary 1c-SApNP (single-component self-assembling protein nanoparticle) platform technology. Each nanoparticle displays 20 copies of uncleaved, prefusion-optimized (UFO) HIV-1 envelope (Env) trimers. UVAX-1197 features a wild-type glycan shield, while UVAX-1107 employs glycan-trimming technology to remove specific glycans, thereby exposing conserved neutralizing epitopes on the HIV-1 Env protein. The combination is designed for active immunization to prevent HIV-1 infection and is currently being evaluated in Phase 1 clinical trials in Australia, administered with CpG 1018 and aluminum hydroxide adjuvants to enhance the immunological response.

Other names: UVAX-1107 + UVAX-1197

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on UVAX-1107 + UVAX-1197.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UVAX-1107 + UVAX-1197.

Explore the full profile